03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
12:05 , Jun 22, 2018 |  BioCentury  |  Finance

Regenerating eastward

Having capitalized on the cell therapy expertise and manufacturing incentives of its European home base, Promethera Biosciences S.A. is expanding to Japan to tap the commitment to regenerative medicines among investors, pharmas and regulators. After...
13:40 , Apr 13, 2018 |  BC Week In Review  |  Company News

Promethera acquires antibody play Baliopharm

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera also raised €9.3 million ($11.4 million) on April 10 through the...
06:45 , Apr 10, 2018 |  BC Extra  |  Company News

Promethera acquires antibody play Baliopharm

Liver disease company Promethera Biosciences S.A. (Mont-Saint-Guibert, Belgium) said it acquired antibody developer Baliopharm AG (Basel, Switzerland). Promethera declined to disclose financial details. Promethera also raised €9.3 million ($11.4 million) through the sale of convertible...
07:00 , May 12, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); tumor necrosis factor receptor 1 (TNFRSF1A; TNFR1; CD120a); HECT domain and ankyrin

Cancer INDICATION: Colorectal cancer; cancer Mouse studies suggest inhibiting TNFRSF1A or RIPK3 could help treat colon and other cancers harboring loss-of-function HACE1 mutations. In a mouse model of HACE1-mutant colon cancer, systemic knockout of TNFRSF1A...